Logo

JW Reports One-Year Follow-Up Results of Relmacabtagene Autoleucel in P-II RELIANCE Study for the Treatment of R/R LBCL at CSCO 2021

Share this

JW Reports One-Year Follow-Up Results of Relmacabtagene Autoleucel in P-II RELIANCE Study for the Treatment of R/R LBCL at CSCO 2021

Shots:

  • The P-II RELIANCE study evaluates relma-cel in 59 patients with r/r LBCL who had failed 2L of therapy- including CD20 agent- anthracycline & patients continue to be monitored for ≥2yrs. for LTO
  • As of Dec 31- 2020 cut-off data- Relma-cel showed durable responses & survival benefit; ORR (77.6%); CR rate (51.7%) & 1yrs. OS (76.8%) with a median follow-up of 17.9mos. The therapy was well-tolerated with a safety profile including a low severe CRS & NT rate of ≥grade 3 (5.1% & 3.4%) & no new safety signals were observed
  • Relma-cel is 1st CAR-T product approved as category 1 biologics in China. The therapy has received PR- BTD & is included in National Significant New Drug Development Program

  | Ref: PR Newswire | Image: FinSMEs

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions